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Abstract
Problem Hospitalized adult patients require more than one short peripheral catheter
(SPC) to complete the prescribed intravenous (IV) therapy due to catheter failure and the
practice of resiting. The purpose of this quality improvement initiative was to increase the
rate of SPCs remaining in situ for the entire duration of the IV therapy for hospitalized
adult patients.
Methods Application of an engineered securement device (ESD), an educational program
pertaining to modifiable risk factors, and changing the practice to removal upon clinical
indication were methods utilized to reduce the number of SPC insertions and catheter
failures. This study was conducted at a rural, Midwestern hospital using a convenience
sample (N=405) and an observational, descriptive, cohort design in six phases between
September 2019 and March 2020.
Results Following the practice changes, there was a reduction of SPC replacement (24%),
catheter failures (24% to 13%), SPCs per patient (M=2.9 to 2.2 p=.045), SPC insertions
(4,000 per year), and zero SPC-related CRBSIs (0.26 per 1000 catheter days to 0.0) and a
significant increase of SPCs remaining in situ (M=2.6 to 3.8 days; p=<.001), resulting in
an estimated cost saving of at least $285,000. The results demonstrated the risk of failure
significantly increased when inserted in the wrist (p=.007) and upper arm (p=.026) and
significantly reduced when inserted in the forearm (p=0.39).
Implications for Practice Study findings suggest the use of an ESD, promoting insertion
in the forearm, avoidance of the wrist and upper arm, and the practice change to removal
when clinically indicated.
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Optimizing The Effectiveness Of Peripheral Intravenous Catheters
Short peripheral intravenous catheter (SPC) insertion is the most common
invasive procedure performed in the hospital (Flippo & Lee, 2011). The intention of a
SPC insertion is for less than 6-days of intravenous (IV) therapy to infuse fluids, blood
products, medications, and contrast media directly into the circulatory system. An SPC is
defined as a catheter less than three inches (7.5 cm) inserted into and terminating in the
peripheral vein of an extremity (O’Grady et al., 2011). There are 330 million SPCs sold
annually in the U.S. (Hadaway, 2012). Furthermore, approximately 60 to 90% of
admitted patients in an acute care hospital are prescribed IV therapy requiring an SPC
(Helm, Klausner, Klemperer, Flint, & Huang, 2015). Interestingly, SPCs do not remain in
situ for the entire duration of the prescribed IV therapy for hospitalized adult patients.
Tan, Tai, Sim, and Ng (2016) found an average rate of 2.82 SPC insertions per patient
admission with an average of 29% failing and 14.9% resited although functioning and
asymptomatic. Hence, approximately 44% of adult patients require more than one
catheter during their hospital stay to complete the prescribed IV therapy.
A vascular access device (VAD) not remaining in situ for the entire intended
duration due to complications is defined as a catheter failure. Undesirable high catheter
failure rates between 16% and 70.7% causing a disruption in IV therapy has been
reported in the literature (Rickard et al., 2018; Shears, 2006; Webster, Osborne, Rickard,
& Marsh, 2019). SPCs have the highest rate of total complications compared to other
VADs (Gunther et al., 2016). One failure initiates a cycle of catheter removal and
reinsertion, further increasing the risk of failure with each subsequent attempt.
Eventually, venous exhaustion occurs resulting in a more costly and higher risk VAD
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being needed. Known VAD-related complications include phlebitis, infiltration,
extravasation, infection, dislodgement, occlusion, and leakage with phlebitis and
infiltration are reported as the most common causes of catheter failure (Helm et al.,
2015).
Not only are patients receiving multiple SPCs due to catheter failure, but also
because of the current practice of routine removal at timed intervals. Functioning,
asymptomatic SPCs are being removed at designated intervals to insert a new catheter
into another site, despite the Infusion Nurse Society (INS) recommendations. The INS
recommended removal of a SPC when clinically indicated, meaning to remove when
there are signs of VAD-related complications or the catheter is no longer needed (Gorski
et al., 2016). In addition, the Centers for Disease Control and Prevention (CDC) updated
the Guidelines for the Prevention of Intravascular Catheter-Related Infections to replace
adult SPCs “no more frequently than every 72- to 96-hrs”, allowing for extended dwell
times (cited in O’Grady et al., 2011 p. 16). This statement is incongruent with the CDC
recommendation for replacement of SPCs in the pediatric population specifically stating
to “replace peripheral catheters in children only when clinically indicated” (cited in
O’Grady et al., 2011, p. 16). High-quality systemic reviews of randomized control trials
(RCTs) have demonstrated no increased risk of phlebitis, infection, infiltration, or
occlusion, and a significant cost savings when SPC sites are changed at routine intervals
compared to removal when clinically indicated (Morrison & Holt, 2015; Webster et al.,
2019).
Currently, at a rural, Midwestern hospital, evaluating and changing SPC practices
pertaining to stabilization and removal when clinically indicated have been identified as
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an area of need. The purpose of this quality improvement (QI) initiative was to increase
the rate of SPCs remaining in situ for the entire duration of the prescribed IV therapy for
hospitalized adult patients. The aim of the project was to decrease SPC replacement by
15% within 6-months. The primary outcome measures of interest were the rate of SPCs
inserted per patient and catheter failures. Secondary outcomes measures included rates of
catheter-related bloodstream infections (CRBSI), gauge, location, stabilization technique,
removal reason, site signs and symptoms, length of stay (LOS), and days in situ. The
questions for study were: In hospitalized adult patients aged 18-years and older requiring
a SPC,
1. how does the use of an engineered stabilization device compared to tape and a
standard transparent dressing for stabilization affect the rate of SPC insertions and
failures over 1-month intervals for a 6-month period?
2. how does replacing the catheter only when clinically indicated compared to
replacing the catheter every 96-hrs affect the rate of SPC insertions over 1-month
intervals for a 6-month period?
Literature Review
The search engines used for this literature review included EBSCO, CINAHL,
PubMed, and Google Scholar and the Cochrane Central Register of Controlled Trials
(CENTRAL). The key search terms were securement, stabilization, dressing, clinically
indicated, dwell, in situ, failure, and intravenous AND catheter AND peripheral. A total
of 89 publications were initially obtained. A refined search with inclusion criteria were
peer-reviewed, full-text, and English-language publications from 1999 through 2019.
Publications were excluded if not human-research, adult population, or SPC study.
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Additionally, an ancestry approach to some references was utilized. Eleven studies from
2006 to 2018, addressing stabilization were selected including one systematic review,
two integrative reviews, five RCTs, two prospective controlled cohort studies, and a
retrospective cohort study. In addition, two systematic reviews from 2015 to 2019
addressing removal when clinically indicated were selected. The following themes
organized the literature review: catheter failure, stabilization, and removal practices.
The high rate of SPC insertions per patient incurs unnecessary pain and anxiety
while multiple attempts with each insertion further increases complications (Helm et al.,
2015). Van Loon et al. (2019) found an 81% first attempt success rate for adult
hospitalized patients. The average rate per insertion is between 2.18 and 2.35 attempts
(Hadaway, 2012). Multiple needlesticks cause frustration for the patient and clinician,
especially when resiting a functioning catheter. Helm et al. (2015) synthesized RCTs
from 1990 to 2014 finding ranges of: phlebitis (0.1% - 63.3%), infiltration (15.7% 33.8%), occlusion (2.5% - 32.7%), dislodgement (3.7% – 9.9%), and CRBSI (0.0% 0.44%). The various complication rates were dependent on inclusion and exclusion
criteria, definitions, indicators, and populations in each study.
Publications have shown significant correlations of specific modifiable risk
factors (MRFs) contributing to catheter failure. A higher rate of phlebitis transpires with
SPCs inserted in an area of flexion and high mobility such as the wrist, antecubital fossa
(AC), hand (Wallis et al., 2014), or dominant extremity (Marsh et al., 2018). Large
catheter diameters (Zhu, Wang, & Wen, 2016) increase the risk of phlebitis while a small
catheter diameter increases the risk of dislodgement (Wallis et al., 2014) and infiltration
(Marsh et al., 2018). Wallis et al. (2014) found upper arm SPCs increase the risk of
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infiltration. Therefore, as demonstrated by Elia et al. (2011), upper arm SPCs have lower
complication rates if longer than 5 cm (14%) compared to less than 5 cm (45%). The INS
Infusion Therapy Standards of Practice recommended to (a) insert in the forearm and
nondominant extremity, (b) avoid areas of flexion, (c) choose a 20- to 24-gauge for most
IV therapies, (d) select a catheter of adequate length for deeper veins, and (e) consider a
stabilization device (Gorski et al., 2016). DeRosenroll (2017) found educating clinicians
about MRFs when selecting the location, laterality, and catheter gauge and length upon
insertion will significantly affect outcomes including catheter failure.
Stabilization devices may minimize catheter micromotion in the vein reducing
premature catheter failure and complications (Fourie, 2015; Marsh et al., 2018). Multiple
products have been promoted for SPC stabilization, each providing a unique method of
securement and cost. Multiple terminologies and synonyms have been utilized among
researchers, clinicians, and professional organizations causing confusion and challenges
when reviewing evidence. To provide clarity, SPC stabilization devices were defined and
categorized into six types: Tape is used in conjunction with gauze or a non-bordered
transparent dressing (standard dressing [SD]); a bordered dressing (BD) is a bordered
transparent dressing; an advanced securement dressing (ASD) is a bordered transparent
dressing with an integrated device for stabilization; an engineered securement device
(ESD) is a device with anchor points or clips for stabilization and used in conjunction
with an SD or BD; and a tissue adhesive is an adhesive such as glue applied topically in
conjunction with an SD or BD. Stabilization device products discussed in the research
include but are not limited to ESDs (Grip-Lok™, StatLock™, VITAL-HOLD™,
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Hubguard™), BDs (Advanced Tegaderm™, Securis™, Veni-Gard™), an ASD
(Sorbaview SHIELD™), and a TA (Hystacryl™).
The original stabilization technique, tape, has been found to increase the risk of
contamination when retrieved from a pocket or adhered to a table prior to application
(Morris & Tay, 2008). A large meta-analysis (N = 10,164) reported a new product
established in 1996 (StatLock™) demonstrated reduced restart rates (67%) and a cost
savings ($18,000 per hospital) compared to tape (Shears, 2006). Subsequently in 2006,
the INS Standards stated to “consider an engineered stabilization device (ESD) to secure
VADs” for the prevention of complications and dislodgement (Gorski et al., 2016, p. 73).
StatLocks™ are also made for stabilizing other healthcare devices ranging from urinary
catheters to drains. StatLocks™ continue to be the most commonly used VAD
stabilization device globally. Since the introduction of the StatLock™, many types of
stabilization devices have been manufactured, utilized, and researched. The Advanced
Tegaderm™ with a winged catheter (WC) was compared to the StatLock™ with a
standard catheter (SC) demonstrating similar failure rates and a cost savings of $2.57 per
insertion with the Advanced Tegaderm™ (Delp & Hadaway, 2011). Studies comparing
the Advanced Tegaderm™ with a SC or WC to a SD with a SC produced low-quality
evidence (deRosenroll, 2017; Fourie, 2015; Jackson, 2012). Marsh, Webster, Flynn, and
Mihala (2015) conducted a small RCT (N = 85) finding catheter failure rates highest with
a SD (38%), BD (25%), ESD (22%), and TA (14%), respectively. TAs have shown to
have antimicrobial properties inhibiting microbial growth (Simonova et al., 2012;
Rickard et al., 2018), but caused skin tears, rashes, and blisters (Marsh, Webster, Flynn,
et al., 2015). A comparison of the Advanced Tegaderm™ compared to a SD in a large
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RCT (N = 628) demonstrated no difference in overall complications for patients (Gunther
et al., 2016). A systematic review evaluated catheter failure identifying low-quality
evidence that one product (SD, BD, or ESD) reduced complications or was superior
(Marsh, Webster, Mihala, & Rickard, 2015). In 2018, a large RCT (N = 1807) comparing
a BD, ESD, TA, and SD found no difference in failure rates and an actual cost savings
with an SD (Rickard et al., 2018). Devries and Strimbu (2019) found over 3-years when
using a BD with a WC there was, “difficulty maintaining a fully intact dressing” so the
organization added a TA to significantly increase the rate of intact dressings from 55% to
98% (Devries & Strimbu, 2019, p. 88).
The 2016 INS Standards stated, “For peripheral catheters, consider two options
for catheter stabilization” such as a WC with a BD or a SC with an ESD (cited in Gorski
et al., 2016, p. 73). The INS Standards further reported a BD with a SC may increase in
situ times, although further research was needed. The INS did not endorse one product,
although recommendations to avoid tape, gauze, and SDs for securement due to
ineffectiveness was specified (Gorski et al., 2016). This was interpreted as the reduction
in failure rates was an affect of the catheter or securement device which must have an
integrated stabilization, such as with an ASD, ESD, or WC.
There are many limitations and minimal strengths of recent SPC stabilization
technique research. While most studies had a significantly reliable sample size, three did
not report the sampling method or size (deRosenroll, 2017; Jackson, 2012; Marsh,
Webster, Flynn, et al., 2015) and one RCT had a small sample size (Marsh, Webster, &
Flynn, et al., 2015). Several studies had limited generalization when conducted in a single
center (Fourie, 2015; Gunther et al., 2016; Marsh, Webster, Flynn, et al., 2015; Marsh,
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Webster, Mihala, et al., 2015) and when inserted in the forearm at an unusually high rate
(80%) (Rickard et al., 2018). No research investigators were blinded due to the nature of
the research; therefore, information bias was a potential in every study. There was a high
risk of bias when researchers received monetary compensation or funding from the
product manufacturer(s) (Bausone-Gazda et al., 2010; deRosenroll, 2017; Flippo & Lee,
2011; Fourie, 2015; Jackson, 2012; Marsh, Webster, Mihala, et al., 2015).
In 1996, the CDC Guidelines were updated to reflect evidence-based research
reflecting adult SPCs were to be removed no more frequently than “every 72- to 96-hrs”
(cited in O’Grady et al., 2011 p. 16). Since then, many high-quality studies evaluating
SPC in situ times and outcomes have been conducted. The Australian Access Teaching
and Research Group (AVATAR) conducted a systematic review to examine the effects of
removing SPCs routinely versus when clinically indicated finding no difference of
phlebitis when removed upon clinical indication (9%) versus routine removal (7.2%)
(Webster, Osborne, Rickard, & Hall, 2010). Based on the emerging evidence, in 2011,
the INS Standards recommended removing SPCs when clinically indicated (Gorski et al.,
2016). Furthermore, AVATAR conducted updated systematic reviews in 2010, 2013,
2015, and 2019 with the last review finding no difference in the in incidence of CRBSI,
thrombophlebitis, all-cause BSI, mortality, or pain (Webster, Osborne, Rickard, & Marsh,
2019). In addition, there was moderate evidence of a $5 per patient cost savings with the
clinically indicated group (Webster et al., 2019). Likewise, Morrison and Holt (2015)
conducted a systematic review finding no difference in phlebitis or infection and reduced
costs and time when practicing removal upon clinical indication.
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In summary, recent research has not identified a superior SPC stabilization
product to standardize practices which may contribute to the limitations of the SPC
studies. This may be due to various study designs, additional variables affecting
outcomes, and product research costs. Multiple interchangeable SPC insertion products
have created a variation of combinations used outside and within organizations. There is
a gap in the literature for large high-quality RCTs to evaluate the effects and cost of all
stabilization techniques and to identify a superior device. Non-manufacturer grant
funding may enable high-quality product research, potentially eliminating conflicts of
interest and investigator bias. Furthermore, additional INS definitions of the different
types of SPC stabilization devices and catheters is needed for researchers and clinicians
to use consist language and have congruent interpretations of evidence when analyzing,
disseminating, and implementing stabilization device research. Based on the evidence
from the literature review, INS Standards, CDC Guidelines, the transition of practice
from routine removal to when clinically indicated, and the addition of an evidence-based
SPC stabilization technique has been recommended to reduce costs and prevent catheter
failures.
The Iowa Model of evidence-based practice to promote quality care, created by
the University of Iowa Hospitals and Clinics, was utilized as the framework for this QI
initiative (Iowa Model Collaborative, 2017). The Iowa Model employs a system’s
perspective to guide clinical decisions when transitioning evidence into practice by
identifying issues, researching solutions, and implementing changes (Iowa Model
Collaborative, 2017). This model begins with the identification of the topic in question
being a problem-focused trigger or a knowledge-focused trigger before the purpose or
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question(s) for study are formulated. Once the problem, purpose, and practice question(s)
are considered a priority for the organization, the QI process begins.
Methods
Design
An observational, descriptive, cohort design was utilized. A retrospective medical
record review was the primary method of data collection. The QI initiative was
implemented in six phases over a 6-month period. Baseline data collection began
September 15th, 2019 during Phase 1 (P1). A nursing education program regarding MRFs
and implementation of an ESD was completed in the designated trial departments in
Phase 2 (P2) starting November 19th, 2019. Patients with a documented or known
contraindication or sensitivity to the ESD had tape and a SD or gauze applied as an
alternative. A nursing education program regarding SPC care and maintenance and a
practice change to clinically indicated was completed in the designated trial departments
in Phase 3 (P3) beginning December 5th, 2019. In addition, simultaneously, applicable
departments received the MRFs and ESD education for implementation hospital-wide. In
Phase 4 (P4), education regarding SPC care and maintenance and a practice change to
clinically indicated was implemented hospital-wide starting January 1st, 2020. The
practice change to clinically indicated was implemented February 3rd, 2020 in Phase 5
(P5). Finally, beginning March 5th, 2020 education and outcomes from the previous
phases was reinforced in Phase 6 (P6).
Setting
The setting was a rural, Midwestern hospital employing more than 1,500
employees with approximately 127 outpatient clinic physicians affiliated with the
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hospital across 24 specialty areas (Mercy, 2019a). Each year, there are over 38,000
emergency department (ED) visits; 5,900 acute inpatient discharges; and 12,000 inpatient
and outpatient surgeries performed at the hospital (Mercy, 2019a). This hospital is part of
a multicenter healthcare organization with 30 acute care hospitals throughout four states
in the Midwest region (Mercy 2019b). The hospital services about 180,000 patients living
and working in the surrounding 17 cities. The county of origin has a population of
slightly over 14,000 with a poverty rate (8.5%) below the state rate of 14.6% and with a
majority race being white (93.3%), which is higher than the state rate of 79.8% (U.S.
Census Bureau, n.d.).
Approval Processes
The Chief Nursing Officer (CNO) and President of the hospital approved the
primary investigator (PI) to facilitate and initiate this QI initiative in collaboration with
the Infection Control nurse. In addition, the university’s doctor of nursing practice (DNP)
committee, institutional review board (IRB), and the hospital’s IRB granted approval.
Benefits of this study included contributions to the decision-making about best practice
for the hospital regarding SPCs. There was minimal risk to subjects as all patient
identifiers of the data were removed and this was a retrospective analysis of nursing
practice.
Sample
A convenience sample of SPCs inserted in adult patients admitted to the hospital
was used in each phase. Inclusion criteria consisted of SPCs in adult patients 18-years of
age or older admitted to the hospital, regardless of diagnosis or medications. Exclusion
criteria consisted of SPCs inserted in pediatric patients 17-years of age or younger
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admitted to the hospital, outpatients including clinic and ED patients who were not
admitted, prehospital insertions, and labor and delivery inpatients.
Data Collection/Analysis
All data was acquired from an SPC audit instrument developed by the PI for QI.
Demographic information was not collected. The rate of SPCs inserted per patient and
catheter failure rates was obtained. Other data included SPC stabilization technique,
gauge, location, removal reason, days in situ, site signs and symptoms, LOS, and CRBSI.
The electronic medical record (EMR) provided six options for the removal reason: per
policy, no longer indicated, site symptoms, per patient, per order, and observed not
present. All data was stored on a password protected computer. Data collection included
a visual site audit completed in a single day at least 4-days after the initiation of each
phase and a chart audit was conducted in a single day at least 7-days following each
visual site audit. Descriptive statistics and statistical analysis using chi-square, Fischer’s
exact, binary logistic regression, ANOVA, and t-tests were conducted based on an alpha
value of p < .05. Failure rates were defined as SPCs categorized as yes for the site signs
and symptoms group or categorized as site symptoms for the removal reason group. The
yes category included observations of erythema, swelling, pain, warmth/cool, and
purulent drainage when observed during the visual audit. The blood category in the site
signs and symptoms group was defined as observed dry or aqueous blood extending
beyond the insertion site.
Procedures
This QI initiative practice interventions were systematically developed using a
plan-do-study-act (PDSA) cycle plan and a timeline. A root cause analysis using a fish-
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bone diagram identified the cause and effects of multiple SPCs per patient (Appendix A).
An evaluation of the hospital’s current practices and the system’s other four hospitals in a
geographic location was undertaken including identification of products, policies,
procedures, documentation, and reporting practices. For the past 2-years, the wound care
specialist performed VAD audits with the assistance of wound care champions while
completing quarterly wound prevalence audits. A pareto chart was devised based on the
audit results (Appendix B). A formal meeting with key stakeholders was employed to
engage the participants, present the plan, decide on a stabilization product and
maintenance practices, and eliminate barriers. The key stakeholders assessed the
stabilization technique options and decided to utilize the StatLock TM ESD for
stabilization based on the literature review. Educational material was developed and
delivered through multiple teaching strategies including a printed bulletin and a 5-minute
roving demonstration. Content included MRFs affecting failure, application and removal
of the ESD, maintenance, and removal procedures. Leadership announced the
implementation dates and the product was stocked and available. A formal meeting was
scheduled after each phase for key stakeholders to collaboratively evaluate and analyze
the data, assess the implementation process, identify what was learned, review
compliance, and decide to adopt, adapt, or abort the interventions.
Results
Between September 15th, 2019 and March 18th, 2020, there were 339 patients with
one or more SPCs (N=405) secured with a SD (n=218) and an ESD (n=187). The SD
category had failure in 19% (n=40) compared to 12% (n=23) in the ESD category. A chisquare test of independence was conducted to examine whether failure and stabilization
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technique were independent of each other. The results were not significant at the .05 level
2

(χ =2.80, df=1, p=.094), suggesting failure and stabilization technique were likely
independent of one another.
During P1 (baseline data), the mean number of SPCs per patient was 2.90
(SD=2.11). Education pertaining to MRFs and stabilization techniques was given to
inserters and the ESD was supplied after baseline data collection in P1. A two-tailed
independent samples t-test was conducted to examine the rate of SPC per patient
difference between the SD category (n=66) and the ESD category (n=82) during P2 and
P3. The mean number of SPCs per patient for the SD category was 2.78 (SD=2.19) and
was significantly higher than the mean for the ESD category 2.08 (SD=1.26) at the .05
level (t=2.32, df=146, p=.021). The number of SPCs per patient was significantly
different between stabilization techniques in P2 and P3, indicating the ESD was more
stabilizing than the SD and resulted in a lower number of SPC restarts.
Likewise, a two-tailed independent samples t-test was conducted to examine the
difference between the number of SPCs per patient from P4 through P6 when the practice
of clinically indicated was implemented hospital-wide. The mean number of SPCs per
patient for the P4 category was 2.29 (SD=1.28) when compared to the P6 category
(M=2.22, SD=1.32) and was not statistically significant at the .05 level (t=0.30, df=119,
p=.767). There was essentially no difference in the number of SPCs per patient between
P4 and P6 despite practicing removal only when clinically indicated.
Next, a two-tailed independent samples t-test was conducted to examine if there
was a difference in the mean number of SPCs per patient between P1 (n=49) and P6
(n=82). The analysis was conducted to evaluate the effect of implementing the
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cumulative SPC education and interventions hospital-wide. The P1 category (M=2.90,
SD=2.11) had a higher rate of SPCs per patient compared to the P6 category (M=2.22,
SD=1.32) and was statistically significant at the .05 level (t=2.03, df=102, p=.045). The
number of SPCs per patient was significantly reduced in P6 following the cumulative
interventions throughout the previous five phases. A trending decrease of SPCs per
patient occurred after P1 (M=2.90, SD=2.11) and continued through P6 (M=2.37
[SD=1.81]; 2.37 [1.76]; 2.29 [1.28]; 2.35 [2.16]; and 2.22 [1.32], respectively) (Appendix
C).
The mean days in situ was 3.11 (SD=2.35) for a total of 1,258 catheter days. The
days in situ increased from P1 (M=2.63, SD= 1.48) to P6 (M=3.74, SD=3.20) correlating
to an average of each SPC in situ for one additional day. An ANOVA was conducted to
determine whether there was a significant difference of days in situ by stabilization
technique. The results indicated no significant difference (F[1, 403] = 3.37, p = .067).
The mean days in situ of the ESD category was 3.34 (SD=2.58) and was greater than the
SD category (M=2.91, SD=2.12). An ANOVA with Tukey pairwise comparisons was
conducted to determine whether there was a significant difference of days in situ by
phase. The results indicated a significant difference (F[5, 399] = 5.09, p < .001) of days
in situ among the phases with P5 and P6 significantly higher than P2. The highest rate of
failures for the in situ group occurred in the zero to 1-day category (n=20, 20%). The
failure rate in the 2- to 4-day category was n=33 (15%), the 5- to 8-day category was n=7
(10%), and the 9- to 25-day category was n=3 (21%). Furthermore, 53 of 63 (84%) failed
SPCs had failed when in situ less than 4-days. Of note, seven of 40 (18%) patients with a
LOS 1-day or less required more than one SPC.
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Analysis of site location demonstrated overall selection in the hand was 37
(9.14%), wrist (n=37, 9.14%), forearm (n=147, 36.3%), antecubital ([AC], n=154,
38.02%), and upper arm (n=28, 6.91%). An increase in forearm selection from P1 (n=16,
33%) to P6 (n=38, 46%) was observed, although the most frequently observed location
was AC (n=154, 38%). A chi-square test of independence was conducted to examine
whether location and phase were independent of each other. The results were not
2

significant at the .05 level (χ =26.68, df=20, p=.145), suggesting location and phase were
likely independent of one another. Therefore, there was not a significant change in the
selection of location following the MRF educational program. A binary logistic
regression was conducted to examine the effect of location on failure rates. The
regression coefficient for the upper arm location was significant
(B=1.15, OR=3.17, p=.026). Failure was likely in the upper arm at 217%. The regression
coefficient for the wrist location was also significant (B=1.26, OR=3.52, p=.007). A
failure was likely in the wrist at 252%. A chi-square test of independence was conducted
to examine if failure and location were independent of each other. The relationship
between location and failure rate was statistically significant at the 0.05 level
(χ2=10.08, df=4, p=.039). Hence, location was related to failure rates. SPCs in the
forearm had a lower observed failure rate (n=14) than expected failure rate (n=22.62)
compared to the hand (n=7, 5.6), wrist (n=10, 5.69), AC (n=24, 23.69), and upper arm
(n=7, 4.31). In addition, the days in situ time was greater when in the forearm (M=3.44,
SD=2.92).
The catheter gauges used were 16 (n=3, 0.74%), 18 (n=57, 14.07%), 20
(n=325, 80%), and 22 (n=20, 4.94%). The 20-gauge catheter was the most frequently
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used catheter size with a steady increase in use from P1 (n=37, 76%) to P5 (n=50, 83%),
but a decreased rate of use occurred in P6 (n=62, 76%). Also, 14 of 57 (25%) 18-gauge
catheters were inserted in the hand and wrist. The days in situ for each gauge catheter
were 16 (M=3.33, SD=0.58), 18 (M=2.77, SD=1.76), 20 (M=3.13, SD=2.43), and 22
(M=3.70, SD=2.64). Interestingly, the mean days in situ was greatest for 22-gauge
catheters (M=3.70, SD=2.64). A Fischer’s exact test was conducted to examine whether
the rate of gauge and phase were independent of each other. The results were not
significant at the .05 level (p=.300), suggesting the rate of gauge and phases were likely
independent of one another. Therefore, there was not a significant change in the selection
of gauge following the MRF educational program. A Fischer’s exact test was also
conducted to examine whether the rate of gauge and failure were independent of each
other. The results were not significant at the .05 level (p=.857), suggesting the rate of
gauge and failure were likely independent of one another. A binary logistic regression
was conducted to examine whether gauge had a significant effect on failure rates. The
results were not significant (χ2=1.30, df=3, p=.728) suggesting gauge did not have an
effect on failure.
In the site signs and symptoms group, there was a low frequency in the yes
category (n=7, 1.73%) and a high frequency in the blood category (n=130, 32.1%). The
frequency in the blood category significantly decreased from P1 (n=30, 42%) to P6
(n=14, 17%). A Fischer’s exact test was conducted to examine whether the rate of site
signs and symptoms and phase were independent of each other. The results were
significant at the .05 level (p=.012), suggesting the rate of site signs and symptoms and
phases were likely not independent of one another. A lower than expected rate of the
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blood category was observed in P3 (24[24.40]), P4 (17[21.19]), and P6 (12[26.32]) and a
lower than expected rate of the yes category was observed in P2 (1[1.24]), P3 (1[1.31]),
P4 (0[1.14]), and P5 (1[1.04]).
The most frequently observed category in the reason for removal group was no
longer indicated (n=145, 36%) compared to per policy (n=35, 9%), site symptoms (n=63,
16%), per patient (n=17, 4%), per order (n=2, 1%), observed not present (n=6, 2%), not
documented but removed at discharge (n=117, 29%), not documented thus removal
unknown (n=20, 5%) (Appendix D). Unfortunately, 137 (34%) of the SPCs did not have
a removal reason documented. A removal time was documented in 117 (85%) of the 137
SPC’s within 2-hrs of being discharged; hence, the reason for removal due to discharge
was assumed. The rate of the site symptoms category immediately decreased from 24%
to 14% after implementing the ESD.
The population’s mean LOS (M=4.77 days) (Appendix E) was greater compared
to the organization’s reported mean from September 2019 to March 2020 (M=2.88 days).
The difference was expected due to the exclusion of labor and delivery patients. There
were 66 (16.3%) patients who had two SPCs concurrently, commonly due to
incompatible or multiple IV infusions. In addition, 34 of 339 (10%) patients required a
central IV catheter during their hospitalization. The number of central IV catheters
inserted per patient decreased from P1 (n=6, 16%) to P6 (n=5, 8%) during the 6-month
study period. A chi-square test of independence was conducted to examine whether the
rate of central IVs and phase were independent of each other. The results were not
2

significant at the .05 level (χ =2.63, df=5, p=.757), suggesting the rate of central IVs and
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phases were likely independent of one another. Finally, the hospital’s total number of
CRBSI was zero during the 6-month period from P1 through P6.
Discussion
In hospitalized adult patients aged 18-years and older requiring a SPC, replacing
the catheter only when clinically indicated compared to replacing the catheter every 96hrs did affect the rate of SPC insertions over 1-month intervals for a 6-month period. The
P1 group had a higher rate of SPCs per patient compared to the P6 group (p=.045). The
number of SPCs required per patient was significantly less in P6 after education of
stabilization techniques and implementation of clinically indicated changing of an SPC
throughout the previous five phases. A steady trending decrease of SPCs per patient
occurred after P1 from an average 2.9 SPCs per patient to 2.37 SPCs per patient in P6.
Regardless of the initial hospital policy of routine replacement at 96-hrs, some SPCs were
remaining in situ longer than 96-hrs prior to implementing a formal practice change to
remove only if clinically indicated. After the practice change, however, the rate of SPCs
in situ after 96-hrs steadily increased from 8% (P1) to 29% (P6). This rate was
comparable to the previously cumulative reported rates of SPCs resited plus SPCs
remaining in despite organizational policies to resite (28.3%). The practice change from
P3 to P6 when hospital-wide implementation occurred, provided a 20% reduction rate of
at least one SPC for patient’s hospitalized between 5- and 8-days, and a 9% reduction rate
of more than one SPC for patient’s hospitalized more than 8-days. Interestingly, one SPC
stabilized with an ESD remained in situ for 25-days in P6, preventing an estimated six
SPCs for one patient (Appendix F).
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In hospitalized adult patients aged 18-years and older requiring a SPC, the use of
an ESD compared to tape and a SD for stabilization affected the rate of SPC insertions
and failures over 1-month intervals for a 6-month period. The baseline rate of 2.9 SPCs
per patient during P1 was comparable to the rate previously reported but significantly
higher than the 2.29 rate in P4 acquired before implementing the practice change to
clinically indicated and the 2.22 rate acquired by the end of P6 (p=.05). When the ESD
was introduced, the average number of SPCs per patient for the SD category (2.78) was
significantly higher (p=.021) than for the ESD category (2.08). In contrast, implementing
the practice change to clinically indicated did not result in a significant difference
(p=.767) in the average number of SPCs per patient in P4 (2.29) compared to P6 (2.22).
Despite statistical insignificance, the average number of SPCs per patient was reduced
between P4 and P6. In fact, a downward trend in the number of SPCs per patient over
time occurred when the ESD and practice change for removal only if clinically indicated
were implemented.
The number of SPCs stabilized with an ESD slightly increased during the study
period. Stabilization selection was at the discretion of the insertor and the majority were
inserted in the ED. Insertors were advised to utilize a SD on ED patients not admitted and
surgical patients with less than an expected 24-hr LOS. The rate of failures decreased
from 24% to 14% immediately after implementing the use of an ESD and MRF
education. The failure rates were lower than previously reported failure rates. The failure
rates are affected by documentation of the removal reason that is based on nursing
selection and is not always complete. This may have contributed to the statistically
insignificant association of stabilization and failure rates. The decreased failure rate, the
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second highest rate of failure occurring in the 0- to 1-day in situ category (20%), and the
rate of patients with a less than 24-hr LOS requiring more than one SPC (18%) support
the use of an ESD for all SPCs including those intended to remain in situ less than 1-day.
There is an opportunity to educate SPC insertors about the increased risk of failure with
using a SD and to promote the usage of an ESD. Consideration for SPC policies to
require an ESD for all inpatients is recommended.
While insertors select the location and gauge, further education is recommended
to address the increased risk of failure when inserted in the upper arm (p=.026) and wrist
(p=.007) and the statistically significant reduced risk of failure when inserted in the
forearm (p=0.39). A high rate of insertions in the AC (38%) may have occurred due to a
misunderstanding that a power injection procedure for computed tomography (CT)
imaging studies must require an AC SPC, although this was addressed during P1 nursing
education. Clarification within organizational policy was addressed to ensure adherence
to the INS Standards and the American College of Radiology suggesting a large forearm
vein was adequate. The result of the 22-gauge SPC having the highest in situ time (3.70
days) was inconsistent with the previously reported higher risk of dislodgement
infiltration, although consistent with the INS Standards. Midline catheters were not
inserted before or during the study period and may have contributed to the rate of central
IV catheters and upper arm SPCs. Midline catheter insertions are being considered for
future implementation. However, there is not a designated vascular access team or nurse
employed at the hospital and may be need to be a consideration. Currently, the critical
care and ED nurses are consulted for difficult SPC insertions. Perhaps a vascular access
nurse may enhance the insertion of midline catheters and prevent the need for central IV
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catheters. The MRFs educational program most likely did not affect the number of SPCs
per patient and the failure rates due to the rate of selecting gauge and location was
insignificantly different among all phases.
Infection is a potential complication from an SPC. While all SPCs had an attached
extension, bonded needleless connectors were substituted with nonbonded needleless
connectors to allow for changing the needleless connector prior to the practice change of
removal when clinically indicated. During the study period, none of the SPCs remaining
in situ beyond 7-days had documentation of the dressing, stabilization technique, and
needleless connector being changed. While there is an opportunity for further education
pertaining to documentation of SPC care and maintenance, astonishingly, the number of
CRBSI was zero when compared to the previous fiscal year (0.26 per 1000 catheter
days). Several factors may have contributed to the zero rate of CRBSI including a
Hawthorne effect, reduction of SPC insertions, introduction of a no-touch antiseptic prep
in the ESD kit, and reduced micromotion when using an ESD. The reduced CRBSI rates
occurred prior to implementation of the interventions, therefore, are most likely the result
of a Hawthorne effect. Regardless, removing a SPC only when clinically indicated did
not increase the rate of CRBSI, and remarkably, produced no infections over a 6-month
period. Further study over a longer period of time or a replication of this study is
suggested.
No SPC major adverse events, skin tears, or allergic reactions were reported
during the study period. Additional SPC practices thought to negatively affect the
outcomes were addressed throughout the phases of the project including: (a) correct use
of an ESD; (b) avoidance of a restrictive dressing (e.g. Coban TM) or blood pressure cuff
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on the SPC extremity; (c) netting (e.g. SurgilastTM) utilized to reduce accidental
dislodgement; (d) securement of the extension set to the skin; (e) and the avoidance of
tape on the catheter hub to prevent improper downward angle, kinking, and occlusion of
the catheter when using an ESD. Thus, over a 6-month period, no additional adverse
events were reported, suggesting intensive education with a careful, methodical approach
to reducing the number of SPCs was effective.
A major strength of this project was reliability as one individual collected all data.
In addition, the PI did not receive monetary compensation from the organization or
manufacturer, thus producing a low risk of bias. A limitation of this project was the
potential overlapping of interventions during phases of the analysis. Recommendations
for future research in SPC stabilization techniques include exploring the effect of the
multiple interchangeable SPC products to identify a superior SPC product combination to
standardize practices. High-quality product research funded by a non-manufacturer may
potentially eliminate conflicts of interest and investigator bias. The effect of utilizing an
ESD for SPCs intended to in situ for patients with a less than 24-hr LOS merits further
investigation. Analysis of staff and patient satisfaction of SPC insertion, care, and
maintenance may provide insight to opportunities for improvement. Furthermore, future
research evaluating the insertor’s reason for location and gauge selection may identify
effective strategies for increasing the use of MRFs to improve outcomes.
Finally, the project aim to decrease SPC replacement by 15% within 6-months
was exceeded as a reduction of 24% in SPC replacement occurred. A cost-benefit
analysis demonstrated this QI initiative may have reduced the number of SPCs by
approximately 4,000 per year. A total savings of at least $285,518 per year related to SPC
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insertion reduction efforts may be realized, including the cost savings realized in the
reduction of CRBSIs.
Conclusion
The combination of using an ESD and practice protocol of replacing SPCs only
when clinically indicated resulted in a 24% reduction in the number of SPCs per patient
and an 11% reduction in the number of catheter failures in a moderately sized, rural
Midwestern hospital. Furthermore, there were no reported cases of CRBSI during the 6month study period. This project promoted safe clinical care, decreased the use of
resources, reduced the disruption of therapy, prevented unnecessary venipunctures, and
resulted in improved outcomes. Since the insertion of an SPC is the most common,
invasive procedure performed in the hospital, interventions to reduce complications
should be a priority for any hospital organization.
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Figure 1. Root Cause Analysis for Cause and Effect Diagram of Multiple SPCs
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Figure 2. Frequency of Causes for Multiple SPCs per Patient

*Causes addressed with study interventions are highlighted
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Figure 3. Summary Results of Number of SPCs per Patient by Phase
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Appendix D
Table 1. Summary Results of Phases
Variable
Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Phase 6 n
Sample Size
49 (12%) 72 (18%) 76 (19%) 66 (16%) 60 (15%) 82 (20%) 405
Stabilization Technique
SD
49 (100%)38 (53%) 44 (58%) 26 (39%) 28 (47%) 33 (40%) 218
ESD
0 (0%)
34 (47%) 32 (42%) 40 (61%) 32 (53%) 49 (60%) 187
Dwell
0-1 day
12 (24%) 28 (39%) 20 (26%) 11 (17%) 11 (18%) 17 (21%) 99
2-4 days
33 (67%) 37 (51%) 43 (57%) 39 (59%) 29 (48%) 42 (51%) 233
5-8 days
4 (8%)
6 (8%) 13 (17%) 16 (24%) 14 (23%) 16 (20%) 69
9-25 days
0 (0%)
1 (1%)
0 (0%)
0 (0%) 6 (10%)
7 (9%) 14
Central IV
6 (16%) 5 (8%)
7 (11%) 7 (13%) 4 (8%)
5 (8%)
34
> 1 SPC Coexisting 10 (20%) 9 (12%) 11 (14%) 10 (15%) 9 (15%) 17 (21%)
66
Location
Hand
5 (10%) 2 (3%)
13 (17%) 5 (8%)
6 (10%) 6 (7%)
37
Wrist
5 (10%) 8 (11%) 7 (9%)
4 (6%)
4 (7%)
9 (11%)
37
Forearm
16 (33%) 22 (31%) 29 (38%) 25 (38%) 17 (28%) 38 (46%) 147
Antecubital
17 (35%) 36 (50%) 23 (30%) 28 (42%) 25 (42%) 25 (30%) 154
Upper Arm
5 (10%) 4 (6%)
4 (5%)
3 (5%)
8 (13%) 4 (5%)
28
External Jugular 1 (2%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
1
Axillary
0 (0%)
0 (0%)
0 (0%)
1 (2%)
0 (0%)
0 (0%)
1
Gauge
16
1 (2%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
2 (2%)
3
18
10 (20%) 9 (12%) 11 (14%) 7 (11%) 5 (8%)
15 (18%)
57
20
37 (76%) 62 (86%) 60 (79%) 54 (82%) 50 (83%) 62 (76%) 325
22
1 (2%)
1 (1%)
5 (7%)
5 (8%)
5 (8%)
3 (4%)
20
Site Signs and Symptoms
WDL
41 (57%) 51 (67%) 27 (55%) 49 (74%) 35 (58%) 65 (79%) 268
Blood
30 (42%) 24 (32%) 21 (43%) 17 (26%) 24 (40%) 14 (17%) 130
Sign or Symptom 1 (1%)
1 (1%)
1 (2%)
0 (0%)
1 (2%)
3 (4%)
7
Removal Reason
Per Policy
4 (8%)
10 (14%) 12 (16%) 4 (6%)
0 (0%)
5 (6%)
35
Site Symptoms
12 (24%) 10 (14%) 11 (14%) 8 (12%) 11 (18%) 11 (13%)
63
Per Patient
4 (8%)
2 (3%)
1 (1%)
3 (5%)
4 (7%)
3 (4%)
17
Per Order
0 (0%)
1 (1%)
1 (1%)
0 (0%)
0 (0%)
0 (0%)
2
Not Present
1 (2%)
1 (1%)
0 (0%)
0 (0%)
1 (2%)
3 (4%)
6
Not Indicated
16 (33%) 19 (26%) 18 (24%) 30 (45%) 22 (37%) 40 (49%) 145
No doc-At DC 12 (24%) 20 (28%) 29 (38%) 17 (26%) 20 (33%) 19 (23%) 117
No doc-Unknown 0 (0%)
9 (12%) 4 (5%)
4 (6%)
2 (3%)
1 (1%)
20
Failure
12 (24%) 10 (14%) 11 (14%) 8 (12%) 11 (18%) 11 (13%)
63

Note. Due to rounding, percentages may not equal 100%.

%
100
53.83
46.17
24.4
55.1
17
3.5
10.03
16.3
9.14
9.14
36.3
38.02
6.91
0.25
0.25
0.74
14.07
80.25
4.94
66.17
32.1
1.73
8.64
15.56
4.2
0.49
1.48
35.8
28.89
4.94
15.56
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Appendix E
Table 2. Summary Results for Number of SPCs, In Situ, Location, Gauge, and LOS
M

SD

n

SEM

Min

Max

Skewness

Kurtosis

2.90
2.37
2.37
2.29
2.35
2.22
2.38

2.11
1.81
1.76
1.28
2.16
1.32
1.73

39
63
65
56
51
65
339

0.34
0.23
0.22
0.17
0.30
0.16
0.09

1.00
1.00
1.00
1.00
1.00
1.00
1.00

9.00
12.00
10.00
5.00
15.00
7.00
15.00

1.46
2.88
1.92
0.78
4.23
1.34
2.71

1.57
11.53
4.53
-0.41
21.46
2.00
11.99

2.63
2.25
2.89
3.17
3.85
3.74
3.11

1.48
1.77
1.76
1.78
2.92
3.20
2.35

49
72
76
66
60
82
405

0.21
0.21
0.20
0.22
0.38
0.35
0.12

0.00
0.00
0.00
0.00
0.00
0.00
0.00

7.00
10.00
8.00
8.00
13.00
22.00
22.00

0.81
1.55
0.74
0.64
1.35
2.62
2.30

0.57
3.99
0.03
-0.26
1.62
11.25
11.23

SD
ESD

2.91
3.34

2.12
2.58

218
187

0.14
0.19

0.00
0.00

13.00
22.00

1.58
2.66

3.68
14.01

Hand
Wrist
Forearm
Antecubital
Upper Arm

2.89
2.46
3.44
2.94
3.29

1.58
2.29
2.92
1.92
1.86

37
37
147
154
28

0.26
0.38
0.24
0.15
0.35

0.00
0.00
0.00
0.00
0.00

7.00
9.00
22.00
12.00
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Appendix F
Figure 4. Bar Chart for Percentage of SPC Days In Situ by Phase

Percentage of SPC Days In Situ by Phase
P1
P2

Phase

P3

P4
P5
P6

24%
0%

67%

8%
39%

1%

8%

51%

26%
0%
0%

57%

17%
17%
24%
18%
23%
10%
21%
20%
9%

59%
48%
51%

Percentage

0-1 day

2-4 days
5-8 days

9-25 days

